Major Shareholder Discloses 15.9% Stake Post-Merger with Lock-Up and Earnout Provisions
VRXA has more than doubled off its 52-week low of $8.4 on elevated volume (3.5× avg).
Summary
Gilbert Edgar Schoeni has disclosed a 15.9% ownership stake in Veraxa Biotech Holding AG following its recent business combination, with shares subject to a lock-up and earnout provisions.
Key Events · Ownership and Investor Activity · VRXA
-
Significant Post-Merger Ownership
Gilbert Edgar Schoeni now beneficially owns 22,539,749 ordinary shares, representing 15.9% of Veraxa Biotech Holding AG following the business combination on June 10, 2026.
-
Lock-Up Agreement in Place
The shares acquired are subject to a lock-up agreement, restricting their transfer for a specified period, which indicates long-term commitment.
-
Performance-Based Earnout Shares
The shareholder is eligible to receive up to 5,000,000 additional earnout shares if the company's stock achieves specific volume-weighted average price (VWAP) targets of $11.00, $12.50, and $14.00 over the next three fiscal years.
Analysis · VRXA · Life Sciences
Gilbert Edgar Schoeni, a significant shareholder, has disclosed a 15.9% ownership stake in Veraxa Biotech Holding AG following its business combination. This filing details the post-merger ownership structure and includes a lock-up agreement, restricting the transfer of shares, and earnout provisions tied to future stock price performance. These terms align the shareholder's interests with the company's long-term success.
How filings like this one have moved
In the 30 days to Oct 4, 2026, 36.7% of the 1015 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.63%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, VRXA was trading at $22.18 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $701.4M. The 52-week trading range was $8.40 to $27.36. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.